research
< Professor Kwang-Hyun Cho's Team >
KAIST researchers have identified five biomarkers that will help them address resistance to cancer-targeting therapeutics. This new treatment strategy will bring us one step closer to precision medicine for patients who showed resistance.
Colorectal cancer is one of the most common types of cancer worldwide. The number of patients has surpassed 1 million, and its five-year survival rate significantly drops to about 20 percent when metastasized. In Korea, the surge of colorectal cancer has been the highest in the last 10 years due to increasing Westernized dietary patterns and obesity. It is expected that the number and mortality rates of colorectal cancer patients will increase sharply as the nation is rapidly facing an increase in its aging population.
Recently, anticancer agents targeting only specific molecules of colon cancer cells have been developed. Unlike conventional anticancer medications, these selectively treat only specific target factors, so they can significantly reduce some of the side-effects of anticancer therapy while enhancing drug efficacy.
Cetuximab is the most well-known FDA approved anticancer medication. It is a biomarker that predicts drug reactivity and utilizes the presence of the ‘KRAS’ gene mutation. Cetuximab is prescribed to patients who don’t carry the KRAS gene mutation.
However, even in patients without the KRAS gene mutation, the response rate of Cetuximab is only about fifty percent, and there is also resistance to drugs after targeted chemotherapy. Compared with conventional chemotherapy alone, the life expectancy only lasts five months on average.
In research featured in the FEBS Journal as the cover paper for the April 7 edition, the KAIST research team led by Professor Kwang-Hyun Cho at the Department of Bio and Brain Engineering presented five additional biomarkers that could increase Cetuximab responsiveness using systems biology approach that combines genomic data analysis, mathematical modeling, and cell experiments. The experimental inhibition of newly discovered biomarkers DUSP4, ETV5, GNB5, NT5E, and PHLDA1 in colorectal cancer cells has been shown to overcome Cetuximab resistance in KRAS-normal genes. The research team confirmed that when suppressing GNB5, one of the new biomarkers, it was shown to overcome resistance to Cetuximab regardless of having a mutation in the KRAS gene.
Professor Cho said, “There has not been an example of colorectal cancer treatment involving regulation of the GNB5 gene.” He continued, “Identifying the principle of drug resistance in cancer cells through systems biology and discovering new biomarkers that could be a new molecular target to overcome drug resistance suggest real potential to actualize precision medicine.”
This study was supported by the National Research Foundation of Korea (NRF) and funded by the Ministry of Science and ICT (2017R1A2A1A17069642 and 2015M3A9A7067220).
Image 1. The cover of FEBS Journal for April 2019
-
event KAIST ISSS Research Session Captivates 150↑ International Scholars, Achieve Major Success
< Photo. Scholars gatheres for NRF Information Session at Chung Keun Mo Hall > KAIST’s International Office, headed by Vice President Soyoung Kim, successfully organized the ‘NRF Information Session for International Scholars’ on September 11, 2024, in collaboration with the National Research Foundation of Korea (NRF). The event was held at KAIST’s main campus to enourage the international scholar’s active participation in research projects and suppor
2024-09-13 -
research KAIST Research Team Proves How a Neurotransmitter may be the Key in Controlling Alzheimer’s Toxicity
With nearly 50 million dementia patients worldwide, and Alzheimers’s disease is the most common neurodegenerative disease. Its main symptom is the impairment of general cognitive abilities, including the ability to speak or to remember. The importance of finding a cure is widely understood with increasingly aging population and the life expectancy being ever-extended. However, even the cause of the grim disease is yet to be given a clear definition. A KAIST research team in the Departme
2022-07-29 -
people Professor Byungha Shin Named Scientist of the Month
Professor Byungha Shin from the Department of Materials Science and Engineering won the Scientist of the Month Award presented by the Ministry of Science and ICT (MSIT) and the National Research Foundation of Korea (NRF) on May 4. Professor Shin was recognized for his research in the field of next-generation perovskite solar cells and received 10 million won in prize money. To achieve ‘carbon neutrality,’ which many countries across the globe including Korea hope to realize, the
2021-05-07 -
people Professor Bumjoon Kim Named Scientist of the Month
Professor Bumjoon Kim from the Department of Chemical and Biomolecular Engineering won January’s Scientist of the Month Award presented by the Ministry of Science and ICT (MSIT) and the National Research Foundation of Korea (NRF) on January 6. Professor Kim also received 10 million won in prize money. Professor Kim was recognized for his research in the field of fuel cells. Since the first paper on fuel cells was published in 1839 by the German chemist Friedrich Schonbein, there has bee
2021-01-22 -
people Scientist of October: Professor Jungwon Kim
Professor Jungwon Kim from the Department of Mechanical Engineering was selected as the ‘Scientist of the Month’ for October 2020 by the Ministry of Science and ICT and the National Research Foundation of Korea. Professor Kim was recognized for his contributions to expanding the horizons of the basics of precision engineering through his research on multifunctional ultrahigh-speed, high-resolution sensors. He received 10 million KRW in prize money. Professor Kim was selected as th
2020-10-15